Scabies Disease

Published Date : Nov 2023
Category : Infectious Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Scabies- A Contagious Skin Ailment

Neglected Tropical Disease (NTD)

A mite infestation causes a skin condition known as scabies, which is highly contagious. Burrowing under the skin, the Sarcoptes scabiei mite produces severe itching. This itching is constant, particularly at night. Family members and intimate skin-to-skin relationships pose the greatest risk because skin-to-skin contact is how the infectious organism is spread. Infested patients need to be identified and treated promptly because an incorrect diagnosis results in epidemics, morbidity, and higher costs. One of the most prevalent dermatological disorders, scabies, contributes significantly to skin disease in developing nations. One of the most prevalent dermatological disorders, scabies, contributes significantly to skin disease in developing nations. WHO stated that it impacts over 200 million people globally at any given time and over 400 million people annually overall.

Sarcoptes scabiei var. Hominis are the skin mites in humans that cause early scabies. It is an arthropod that is a member of the Acarina order. It is a member of the family Sarcoptidae, order Astigmata and class Arachnida. In terms of clinical presentation, it is present as either the classic, nodular, or scabies contagious crusted variant known as Norwegian scabies. The female mite initiates the infestation by burrowing in its host's stratum corneum to deposit its eggs. Afterward, it gives rise to larvae, nymphs, and adults.

In the classic form of scabies, an individual has anywhere from 10 to 15 mites in their population. In cases of classic scabies, mites usually need ten minutes of skin-to-skin contact to spread to a new human host. Additionally, the disease spreads through bed linens or clothing that has been contaminated with fomite.  Hyperkeratotic plaques, which diffuse or localize to the palms, soles, and undernails, are a common presentation of scabies. One variation of the classic form of scabies is the nodular form.  This type is defined by erythematous nodules that are more prevalent in the groin and axilla. The itchy nodules are thought to be an allergic reaction to the female mite. A single person with Norwegian scabies, the crusted variety, has up to millions of scabies mites on them. Patients with impaired immune systems because of immunosuppressive medication, diabetes, HIV infection, or advanced age are susceptible to crusted scabies. For infection to occur in this high density, there needs to be short contact with patients and contaminated materials.

Scabies is a disease that affects people worldwide, but it is more prevalent in tropical regions with limited resources, especially in children and the elderly. Children in these environments have a prevalence of anywhere between 5% and 50%. Infestations that recur are frequent. Healthcare systems bear a significant financial burden due to the infestation of scabies and its associated complications. In high-income nations, cases are rare, but outbreaks in hospitals and communities where people are most vulnerable result in large financial losses for the country's health care system. Scabies outbreaks have been related to acute post-streptococcal glomerulonephritis, a kidney disease. This has been proved by numerous studies. An increasing amount of research links Streptococcus pyogenes-caused impetigo to the pathophysiology of rheumatic fever and rheumatic heart disease.

In response to requests from Member States and the suggestions of the WHO Strategic and Technical Advisory Group for NTDs, the WHO classified scabies as Neglected Tropical Diseases (NTDs) in 2017.WHO 2030 scabies global targets include: countries to include scabies treatment in the comprehensive care package for universal health coverage and countries to carry out MDA interventions in endemic regions (individuals with a prevalence of 10% or higher).WHO develops response plans for managing scabies outbreaks in collaboration with partners and Member States. To enable rapid and cost-effective adoption of the strategy, WHO advises that scabies control measures be incorporated into an integrated skin NTDs approach that is specific to the illnesses prevalent in each nation.  The WHO has now listed ivermectin as an essential medicine for treating scabies, and several suppliers have received WHO prequalification.

DiseaseLandscape Insights assists the stakeholders by providing data related to the scabies disease marketplace, knowledgeable choices in healthcare equipment, therapies, and diagnostic techniques where various new technologies and innovations are impacting the disease market and driving higher expansion.

Scabies Diagnostic Analysis:

Scabies are typically diagnosed by visualization of the scabies rash as well as patient history. Scabies are diagnosed by visualizing mites in skin gratings in the stratum corneum. This method often fails the correct diagnosis because of the high chance of sampling error.

Other methods, like non-invasive videodermatoscopy, are utilized during the physical examination.  This technique has not yet become mainstream thought the Dermatology community.

Videodermatoscopy makes it possible to examine the skin's surface up to the superficial dermis, making it useful for identifying managed mites, burrows, eggs, larvae, and excrement. There are various benefits to videodermatoscopy over conventional skin scrapings. First off, kids, delicate patients, and people who might object to skin scrapings are more likely to accept its non-invasive nature. In addition, it is quicker and easier to execute than the conventional microscope method. Dermoscopy, also known as dermatoscopy, is a portable alternative to videodermatoscopy that doesn't require a computer connection. A skin biopsy is used to confirm the diagnosis if it is unidentified. A recently created serologic test helps in the diagnosis of scabies in addition to biopsy.

Scabies Diagnostic Market Players:


Key Players

Canfield D200 EVO video dermatoscopy

Canfield Scientific Inc.

Demolition Plus

Tre T Medical Group

MoleScope II

IDCP MedTech

Video dermatoscope medicam components

FotoFinder Systems

Video dermatoscope DE370

Firefly Global

Video dermatoscope VTRACK 4.0


The market for the diagnosis of Scabies is very crowded and competitive. Market participants should use new technology to produce a variety of diagnostic products. The development of rapid, low-cost diagnostic tests is also crucial in the diagnosis of Scabies. The development of single accurate diagnostic tests for Scabies is essential nowadays.

DiseaseLandscape Insights assists the industry leader in the use of new technologies for improving the existing diagnostic method and provides data on current market players and their products for more knowledge about market dynamics. By using the data from DLI, stakeholders choose the path of their business and implement strategies for the growth of the market.

Scabies Treatment Analysis:

Scabies are treated with topical scabies creams and in more severe cases oral medication. Itchiness frequently gets worse for 1–2 weeks after treatment starts. Topical treatments that are applied to the whole body include about 5% over-the-counter permethrin cream, 0.5% malathion in an aqueous base,10–25% benzyl benzoate emulsion, and 5–10% sulphur ointment.

Oral Ivermectin is also very effective, but pregnant women and children under the weight of 15 kg should not take it. The consequences of scabies require additional therapies. Impetigo and bacterial skin infections are treated with antibiotics or antiseptics.

Defining the cause helps prevent further infection and limit community outbreaks, as treatment failure is common. Failure to treat close contacts at the same time, to decontaminate clothing and bedding during treatment, and noncompliance with the prescribed course of action are all contributing factors to treatment failure.  Ivermectin-resistant Sarcoptes mites are the cause of treatment failure for crusted scabies. The suggested treatment for scabies in humans for known ivermectin resistance is moxidectin.

Scabies Treatment Market Players:


Key Players

Scab X



Cannote Healthcare

New Ivermectol 12mg

Sun Pharmaceutical Industries Ltd

Ivertreat 12mg

Zydus Cadila

Lupimectin 12mg

Lupin Limited

Ivecop 12mg

A. Menarini India Pvt Ltd


Manus Aktteva Biopharma LLP

The market for canine scabies treatment offers a variety of options for businesses. The market participants concentrate on producing a variety of affordable therapeutic items and repurposing existing medications using new technologies to improve patient health and boost business profits.

Market players explore and thrive in the Scabies therapy business by utilizing the market research and consulting services provided by DiseaseLandscape Insights. By conducting thorough studies of treatment options, new products, and technology, we assist customers in remaining strong and one step ahead of the competition. When it comes to organizing, carrying out, and assessing clinical trials for the creation of new medications, DLI services offer invaluable support.

Recent Development:

Treatments for scabies that have an extended half-life or possess ovicidal qualities would be revolutionary. Because pigs and humans have comparable genetic makeup, skin physiologies, and immune systems, new anti-scabies medications are presently being researched and tested on porcine hosts. Afoxolaner, a new acaricide, or moxidectin, a highly lipophilic macrocyclic lactone, proved to be more effective in a single dosage than in two doses of ivermectin in two pre-clinical experiments. In contrast to the 100% cure for scabies rate among the pigs treated with moxidectin, a porcine investigation showed that only 50% of the 12 pigs treated with ivermectin were healed by day 14. Compared to ivermectin, which is detectable in plasma for just 7 days, moxidectin has a longer half-life and is present for at least 47 days. Moxidectin is being tested as a novel single-dose medication in a phase II clinical investigation.

Notably, fluralaner has replaced Ivermectin and Moxidectin as the therapy of choice for S. scabiei infection, which is referred to as "mange" in animals and is typically treated in cats and scabies in dogs. This is because the fluralaner is safe, effective, and to provide the host with longer-lasting protection. A growing body of research in veterinary medicine on the use of fluralaner in several mammal species points to fluralaner as a potential avenue for human scabies research.

Regulatory Framework:

According to TGA (Therapeutic Goods Administration), on 1 June 2023, the prescribing restrictions on ivermectin have been removed and uses are no longer limited to specialists such as dermatologists, gastroenterologists, and infectious diseases specialists. Various clinical studies have recognized ivermectin does not improve outcomes in patients with COVID-19. The National Clinical Evidence Taskforce (NCET) and many similar bodies around the

world, including the World Health Organization, strongly advises against the use of Ivermectin for the prevention or treatment of COVID-19.

Ivermectin for oral use is only a prescription (Schedule 4) medicine in the Poisons Standard. It is only approved by the TGA for the treatment of scabies and river blindness (onchocerciasis).

The restriction on Ivermectin was announced in September 2021 because of concerns about the safety of consumers using ivermectin without health advice to treat COVID-19, prevalent use of ivermectin as an alternative to approved vaccines and treatments for COVID-19, and potential shortages of the medicine for approved uses.

The application to remove restrictions was the basis for the final decision, which was reached in compliance with the Therapeutic Goods Act 1989's procedures. It considers feedback from two rounds of public consultation as well as recommendations from the impartial Advisory Committee on Medicines Scheduling (ACMS).

Clinical Trial Assessment:

The government's growing focus on comparative effectiveness research highlights the significance of clinical trials for evidence-based medicine and healthcare reform. One of the main objectives of health care reform is accomplished with the aid of clinical data, which enables market participants to correctly compare medical therapy.

The table below lists the study names of the ongoing clinical trials along with the stages at which they are being carried out.

Phase 1

Phase 2

Phase 3

Phase 4

Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies

Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)

Prospective, Open-label, Multicenter, Initially Single-armed and in Case of Treatment Failure Subsequently Three-armed Randomized Clinical Trial of Phase III/IV Investigating the Escalated Therapy of Scabies with INFECTOSCAB 5% (Permethrin)

Comparison of Effectiveness Between Three Dosages of Oral Ivermectin, Two Dosages of Oral Ivermectin, and Two Applications of Topical Permethrin in Scabies Patients

Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies

A Phase 2, Placebo-controlled, Double-blind, Randomized, Dose-Ranging, Efficacy and Safety Study of Orally Administered Moxidectin in Adults with Scabies.

Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children: A Cluster Multicenter Randomized Trial

A Single Treatment Pharmacokinetic and Safety Study of Natroba (Spinosad) Topical Suspension 0.9% w/w in Subjects 1 Month to 3 Years 11 Months of Age with an Active Scabies Infestation


A Phase 2, Placebo-controlled, Double-blind, Randomized, Dose-Ranging, Efficacy and Safety Study of Orally Administered Moxidectin in Adults with Scabies.

A Double-Blind, Two Arm, Multicenter, Randomized, Parallel Group, Bioequivalence Study with Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects with Scabies

A Randomized Controlled Trial Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon


A Randomised, Double-blind, Placebo-controlled Trial to Assess the Safety, Pharmacokinetics, and Efficacy of Escalating Doses of Oral Ivermectin in Scabies Infected Children Weighing 5 to Less Than 15 Kilograms

A Multi-center, Double-blind, Randomized, Parallel-group Study Comparing Permethrin Cream, 5% With Elimite™ in Patients with Active Scabies.



Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies - Impact on Impetigo and Skin Microbiology


DiseaseLandscape Insights (DLI) helps producers create and execute workable solutions to stop and control outbreaks of Scabies. Furthermore, because of increased awareness and predicted epidemics, there is a growing demand for Scabies therapy, clinical assessments, and diagnostic tools.

DiseaseLandscape Insights provides key players in the production of therapeutic commodities with vital information and experience. With the help of DiseaseLandscape Insights, market participants more easily plan and execute clinical trials for novel drugs and pharmaceuticals, patient recruitment strategies, and regulatory compliance.

DLI also gives industry participants comprehensive information about global regulations and guidelines, market trends, and rivals in the sector. DLI helps all players in the market establish a more solid presence in the healthcare industry.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape